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Abstract
Introduction: The majority of deaths from breast cancer are a result of metastases; however, little is understood
about the genetic alterations underlying their onset. Genetic profiling has identified the adhesion molecule
plakoglobin as being three-fold reduced in expression in primary breast tumors that have metastasized compared
with nonmetastatic tumors. In this study, we demonstrate a functional role for plakoglobin in the shedding of
tumor cells from the primary site into the circulation.
Methods: We investigated the effects of plakoglobin knockdown on breast cancer cell proliferation, migration,
adhesion, and invasion in vitro and on tumor growth and intravasation in vivo. MCF7 and T47D cells were stably
transfected with miRNA sequences targeting the plakoglobin gene, or scramble vector. Gene and protein
expression was monitored by quantitative polymerase chain reaction (qPCR) and Western blot. Cell proliferation,
adhesion, migration, and invasion were measured by cell counting, flow cytometry, and scratch and Boyden
Chamber assays. For in vivo experiments, plakoglobin knockdown and control cells were inoculated into mammary
fat pads of mice, and tumor growth, shedding of tumor cells into the bloodstream, and evidence of metastatic
bone lesions were monitored with caliper measurement, flow cytometry, and microcomputed tomography (μCT),
respectively.
Results: Plakoglobin and g-catenin expression were reduced by more than 80% in all knockdown cell lines used
but were unaltered after transfection with the scrambled sequence. Reduced plakoglobin resulted in significantly
increased in MCF7 and T47D cell proliferation in vitro and in vivo, compared with control, with significantly more
tumor cells being shed into the bloodstream of mice bearing plakoglobin knockdown tumors. In addition,
plakoglobin knockdown cells showed a >250% increase in invasion through basement membrane and exhibited
reduced cell-to-cell adhesion compared with control cells.
Conclusion: Decreased plakoglobin expression increases the invasive behavior of breast cancer cells. This is the first
demonstration of a functional role for plakoglobin/g-catenin in the metastatic process, indicating that this molecule
may represent a target for antimetastatic therapies.
Introduction
Breast cancer is a highly metastatic disease, and once
metastases are established, this condition becomes
incurable. In 65% to 75% of patients with advanced
breast cancer, skeletal involvement is present, with
median survival rates of approximately 2 years after
initial diagnosis of bone metastasis [1]. However, little is
understood about the genetic alterations that are
responsible for changing a nonmetastatic tumor into a
tumor with a metastatic phenotype. Identification of
these genes and their functional significance is therefore
essential for the development of novel therapeutic
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Genetic profiling has identified the adhesion molecule
plakoglobin as being the gene most significantly altered
in breast cancer that has metastasized to bone and
lymph node compared with nonmetastatic tumors;
metastatic tumors showed a threefold reduction in
expression of this gene [2]. Furthermore, expression of
plakoglobin is reduced on autocrine production of
human growth hormone, which is associated with
increased breast tumor cell invasion in vivo [3]. Plako-
globin resides on the same locus as the BRCA1 gene,
17q12-17q21, and patients showing loss of heterozygos-
ity of BRCA1 also show loss of heterozygosity of plako-
globin [4,5]. Patients with this mutation have an 80%
chance of developing breast cancer, further suggesting a
role for plakoglobin in the etiology of breast cancer [6].
For metastases to develop, tumor cells must first
acquire a motile phenotype and migrate toward the
basement membrane. Breakdown of the extracellular
matrix then allows the cells to invade the surrounding
tissue and enter the bloodstream or lymphatic system.
Once in the circulation, cells must evade the host
immune system before exiting the vasculature by
adhering to the endothelium of the target site. Finally,
tumor cells implant at a secondary site, forming a
metastases [7]. Therefore, genetic alterations that lead
to disruption of cell-cell and cell-matrix interactions
may play a role in the initiation of cancer metastases,
facilitating tumor-cell dissemination from the primary
site into the circulation.
Plakoglobin encodes for the cell-adhesion protein g-
catenin [8,9]. In conjunction with b-catenin, g-catenin
links e-cadherin to the actin cytoskeleton, forming inter-
cellular cadherin-catenin complexes, a key part of the
extracellular matrix [10]. In this study, we aimed to
establish whether plakoglobin has a functional role in
the metastatic cascade in breast cancer. We investigated
the effects of reducing plakoglobin expression on the
invasive properties of breast cancer cells by using
miRNA technology. We have designed small ssRNA
sequences of approximately 22 nucleotides in length
that trigger gene silencing through specific cleavage and
RNA degradation to target plakoglobin exclusively
[11,12]. We compared the effects of reduced plakoglobin
expression in weakly metastatic MCF7 and nonmeta-
static T47D breast cancer cells on growth, adhesion,
migration, and invasion in vitro [13-16]. In addition, we
analyzed tumor growth and intravasation from the
mouse mammary fat pad into the circulation in vivo.
Our data show that loss of plakoglobin promotes the
prometastatic phenotype of breast cancer cells, indicat-
ing that this molecule may be a potential prognostic fac-
tor of increased risk of cancer progression as well as a
therapeutic target.
Materials and methods
Generation of plakoglobin knockdown cell lines
Pre-miRNA expression cassettes were designed to target
the plakoglobin gene by using the BLOCK-iT Pol II miR
RNAi Expression vector kits and manufacturer’s instruc-
tions. In brief, complementary DNA oligos containing
four-nucleotide overhangs were designed by using the
RNAi Designer online tool (Invitrogen, Carlsbad, CA,
USA) and synthesised by using the following primer
pairs: 2 = Forward (5’ to 3’): TGC TGA TGA GAT
GCA CAA TGG CCG ACG TTT TGG CCA CTG ACT
GAC GTC GGC CAG TGC ATC TCA T Reverse (5’ to
3’): CCT GAT GAG ATG CAC TGG CCG ACG TCA
GTC AGT GGC CAA AAC GTC GGC CAT TGT
GCA TCT CAT C. 3 = Forward (5’ to 3’): TGC TGA
TTG CTG GGA CAC ACG GAT AGG TTT TGG
CCA CTG ACT GAC CTA TCC GTG TCC CAG CAA
T Reverse (5’ to 3’): CCT GAT TGC TGG GAC ACG
GAT AGG TCA GTC AGT GGC CAA AAC CTA
TCC GTG TGT CCC AGC AAT C. Double-stranded
oligos were then cloned into pcDNA6.2-GW/EmGFP-
miR expression vectors by using T4 DNA Ligase before
being transformed into One Shot TOP10 Competent
Escherichia coli. Transformed E. coli was plated onto LB
agar, Miller (Sigma-Aldrich, Poole, UK) containing 100
μg/ml nucleoside antibiotic (Blasticidin; Invitrogen). To
check accuracy of cloning and transformation DNA
from five individual Blasticidin-resistant colonies per
original double-stranded oligo was purified by using
PureLink HQ Mini Plasmid purification Kit (Invitrogen),
sequenced in house by using the random shotgun
method by the Genomics core facility, University of
Sheffield, as previously described; data were analyzed by
using Finch TV software and data cross referenced to
the plakoglobin sequence on Genbank [Genbank:
AC000149] [17,18]. To enable lentiviral transfection, the
pre-miRNA expression cassettes were then transferred
to pLenti6/V5-DST destination vector (as described in
BLOCK-iT Lentiviral PolII miRNAi Expression System
manual, available online) [19]. Pre-miRNA cassettes and
ViraPower (Invitrogen) were co-transfected into a
293FT donor cell line by using Lipofectamine 2000
(Invitrogen) to produce a replication-incompetent lenti-
virus. Lentivirus containing pre-miRNA cassettes or
control (scramble miRNA sequence) were used to trans-
duce the human breast cancer cell lines T47D and
MCF7 to produce three plakoglobin-knockdown and
control cell lines.
Real-time PCR
Total RNA was extracted with Trizol (Invitrogen), before
reverse transcription by using superscript III (Invitrogen);
the resulting cDNA was used as a template for real-time
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quantitative PCR. Cells from three separate in vitro
experiments or five tumors per in vivo group were ana-
lyzed separately. Relative mRNA expression of plakoglo-
bin (Hs00984034_m1; Applied Biosystems), e-Cadherin
(Hs1013953_m1), or NM23-H1 (Hs00264824_m1) were
compared with the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; Hs99999905_m1) by
using an ABI 7900 PCR system (Perkin-Elmer, Applied
Biosystems) and Taqman universal master mix (Applied
Biosystems). Relative mRNA was determined by using
the formula 2-ΔCT (CT; cycle threshold) where ΔCT =
CT (target gene) - CT (GAPDH).
Western blotting
Protein was extracted from pooled cells from three
separate in vitro experiments and tumor samples from
individual mice by using a Mammalian cell lysis kit
(Sigma-Aldrich, Poole, UK). Ten micrograms of protein
was run on a 10% polyacrylamide gel and transferred
onto an imibilon-P nitrocellulose membrane (Millipore).
Nonspecific binding was blocked with 1% casein (Vector
Laboratories) before incubation with mouse monoclonal
antibodies specific for gamma-catenin [15F11] (1:500),
e-cadherin [HECD-1] (1:1,000), or GAPDH [6C5]
(1:1,000) for 16 hours at 4°C (all primary antibodies
were from AbCam, Cambridge, UK). Secondary antibody
was sheep anti-mouse horseradish peroxidase (HRP;
1:15,000), and HRP was detected with the Supersignal
chemiluminescence detection kit (Pierce). Band quantifi-
cation was carried out by using Quantity One software
(Bio-Rad, Hemel Hempstead, UK) and normalized to
RNA polymerase.
Immunohistochemistry
Immunohistochemistry was performed on 4% formalin-
fixed cells grown on chamber slides. Primary antibodies
rabbit anti-g catenin (2309s, 1:500 dilution; New England
Biolabs), rat anti-e-cadherin (DECMA-1, 1:50; AbCam),
and rabbit anti- b-catenin (E247, 1:50; AbCam). Cells were
subsequently incubated with biotin anti-rabbit (for g-cate-
nin and b-catenin at 1:100) and biotin anti-ray (for e-cad-
herin at 1:100). Visualization followed incubation with
fluorescence avidin (Vector A-2001) at 1:250.
nalysis of prometastatic parameters in vitro
All cell lines were maintained in RPMI-1640 supplemen-
ted with 10% FCS (Gibco Invitrogen, Paisley, UK) and
50 mg/ml blasticidin, 24 hours before experimental proto-
col cells were transferred to RMPI-1640 supplemented
with 10% FCS in the absence of blasticidin. All experi-
ments were carried out in triplicate and repeated 3 times.
Cell proliferation was monitored every 24 hours for
96 hours by cell counting with a 1/400 mm2 hemocyt-
ometer (Hawksley, Lancing, UK), and a sample of cells
was taken at each time point for Western blotting and rt-
PCR to check the stability of the siRNA knockdown.
Cell-cell adhesion was monitored by using two meth-
ods: (a) the ability of cells to form three-dimensional
spheroids after seeding of 2,000 cells into a semisolid
medium. Medium consisted of 1.5% agarose (Invitrogen)
in RPMI media supplemented with 1% fungizone
(Sigma-Aldrich) and 1% streptomycin (Sigma-Aldrich).
The spheroid area was calculated 10 and 21 days after
seeding by using ImageJ software (ImageJ v1.44;
National Institutes of Health, Bethesda, MD, USA); and
(b) the ability of cells to bind to a confluent monolayer
of the corresponding cell type; cells were cultured to
form a confluent monolayer, and 20,000 cells of the
same type (plakoglobin knockdown or control) were
labeled with 1 nM DiD (Invitrogen, Molecular Probes)
for 30 minutes in serum-free media before being seeded
onto the equivalent confluent cells. Two hours after co-
culture, media containing floating cells were discarded,
and adherent cells were trypsinized. The number of
DiD-labeled cells that had adhered to nonlabeled cells of
the same cell type was analyzed at 644 nM with flow
cytometry.
Tumor cell invasion was assessed by using 6-mm
Transwell plates with an 8.0-μm pore size (Costar;
Corning Incorporated, Corning, NY, USA) either
uncoated or coated with basement membrane matrix
(Matrigel; Invitrogen). Cells were seeded into the inner
chamber at a density of 2.5 × 105 and 5 × 105 per assay
in RPMI without FCS, and RPMI supplemented with
FCS was added to the outer chamber. Twenty-four
hours after seeding, cells were removed from the top
surface of the membrane, and cells that had invaded
through the pores were stained with hematoxylin and
eosin. Invasion was calculated as the percentage of cells
that invaded through basement membrane compared
with cells that had moved to the underside of uncoated
plates. Numbers of cells were counted by using a DMRB
microscope (Leitz, Germany) and OsteoMeasure XP
v1.2.0.1 program (Osteometrics, Decatur, GA, USA).
Migration of tumor cells was investigated by analyzing
wound closure: Cells were seeded onto 0.2% gelatin;
once confluent, 10 µg/ml mitomycin C was added, and
a 50-μm scratch made across the monolayer. The per-
centage of wound closure was measured at 24, 48, and
72 hours. To monitor migration of individual tumor
cells, a 50-μm scratch was made across the monolayer
of confluent cells. Images were taken every hour for
72 hours by time-lapse microscopy by using a CTR7000
inverted microscope; images were captured by using
LAS-AF v2.1.1 software (Leica Applications Suite; Leica
Microsystems, Wetzlar, Germany) and analyzed by Ima-
geJ software (ImageJ v1.44; National Institutes of
Health).
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Effects of altered reduced plakoglobin expression on
tumor growth and metastases in vivo
Analysis of tumor growth in vivo
17b estradiol pellets (Innovative Research of America)
were implanted subcutaneously into 50, 11-week-old
female balb/c nu/nu mice (Harlan, Shardlow, UK). Seven
days after the pellet had been implanted, 1 × 105 MCF7
3c-3 or control cells (n =15 per group) or 1 × 105 T47D
2A-4 or control cells (n = 10 per group) in 20 μl (33%
Matrigel: 66% PBS) were inoculated into the fifth and 10th
mammary fat pads. Tumor volume was measured twice
per week by using calipers. For differences in tumor
growth, 10 mice per group were culled by cervical disloca-
tion 32 or 34 days after tumor cell implantation. For analy-
sis of circulating tumor cells, five mice per group bearing
MCF7 3c-3 or control cells were culled once tumors were
of equal size (1 cm3 ). Tumors were placed in cell-lysis
buffer (MCL-1KT mammalian cell-lysis kit (Sigma, Poole,
UK)), and protein was extracted according to the manu-
facturer’s instructions. Experiments were carried out with
UK Home Office approval under project license 40/2343.
Isolation of circulating tumor cells
Whole blood was analyzed from five mice per group bear-
ing 1-cm3 tumors from MCF7 3C-3 or control cells.
Whole blood from three naïve mice and parental MCF7
cells were used for staining controls by using the protocol
described in Ottewell et al. [20], with the exception that
the primary antibody used was anti-human EpCAM anti-
body directly conjugated to phycoerythrin (PE) (Clone
1B7; 1:50; eBioscience, Hatfield, UK). PE-positive cells
were plated directly into a 96-well tissue-culture plate
(one well per group) (Nunc, Rochester, UK) on a MoFlow
High performance cell sorter (Beckman Coulter, Cam-
bridge, UK). PE fluorescence was detected with a 555LP
dichroic long-pass and a 580/30-nm band-pass filter.
Acquisition and analysis of cells was performed by using
Summit 4.3 software. After sorting, cells were cultured in
RPMI medium supplemented with 10% FCS.
Microcomputed tomography imaging
Microcomputed tomography analysis of tibiae and femurs
were carried out by using a Skyscan 1172 x-ray-computed
microtomograph (Skyscan, Aartselaar, Belgium) equipped
with an x-ray tube (voltage, 49 kV; current, 200 μA) and a
0.5-mm aluminum filter. Pixel size was set to 4.37 μm, and
scanning was initiated from the top of the proximal tibia
or the distal femur. For each sample, 275 cross-sectional
images were reconstructed with NRecon software (version
1.4.3, Skyscan). After reconstruction, the volume of inter-
est was defined on the two-dimensional acquisition images
by using a hand-drawing tool. Trabecular bone volume
fraction (BV/TV), the ratio of the volume of bone present
(BV) to the volume of the cancellous space (TV), was
calculated for 1 mm of the bone, starting 0.2 mm from the
growth plate. 3D modeling and analysis were performed
by using CTAn (version 1.5.0.2) and CTvol (version
1.9.4.1) software (Skyscan).
Statistical analysis
Statistical analysis was carried out by using analysis of
variance (ANOVA) followed by the Dunnett two-sided
multiple comparison test. All P values are two-sided.
Results
Plakoglobin expression in parental cell lines
The main aim of this study was to investigate whether
expression of the cell-adhesion molecule plakoglobin
plays a role in the dissemination of breast cancer cells
into the circulation. We first compared the expression of
plakoglobin in weakly metastatic MCF7, nonmetastatic
T47D, and highly metastatic HeLa, MDA-MB-436, and
MDA-MB-231 cell lines [13-16,21-24]. Real-time PCR
analysis showed significantly higher levels of plakoglobin
in MCF7 and T47D breast cancer cells compared with
HeLa, MDA-MB-231, or MDA-MB-426 (P < 0.0001 for
T47D cells and P < 0.005 for MCF7 cells compared with
HeLa, MDA-MB-231, or MDA-436) (Figure 1A).
Furthermore, significantly higher levels of plakoglobin
were detected in T47D cells compared with MCF7 (P <
0.005). In all cell lines tested, plakoglobin gene expression
correlated with g-catenin protein expression (Figure 1C).
The protein product of plakoglobin, g-catenin, com-
plexes with e-cadherin to form intercellular bonds; we
therefore examined the gene and protein expression of e-
cadherin in the highly metastatic versus weakly and non-
metastatic cell lines. Real-time PCR and Western blot
analysis showed high levels of e-cadherin in T47D and
MCF7 cells, whereas this gene was undetectable in HeLa,
MDA-MB-231, and MDA-MB-436 cells (Figure 1B).
Similar to plakoglobin expression, significantly less e-cad-
herin was detected in MCF7 cells compared with T47D
(P < 0.005). As both plakoglobin and e-cadherin were
detectable in MCF7 and T47D cells, these cell lines were
selected as models for investigating the effects of reduced
plakoglobin on parameters associated with metastases
after targeted miRNA knockdown.
Effects of miRNA transfection on plakoglobin expression
To produce T47D and MCF7 cells with reduced levels
of plakoglobin, pre-miRNA expression cassettes were
designed to target the plakoglobin gene, and control
cells were produced by using scramble sequence. Pre-
miRNA cassettes were transfected into MCF7 and T47D
cells, and six clones from each transfection were tested
for plakoglobin expression. Transfection with scramble
sequence had no effect on plakoglobin expression;
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however, transfection with miRNA 2 resulted in a 58%
to 81% reduction in plakoglobin expression in MCF7
cells (Figure 2A) and a 0 to 90% reduction in expression
in T47D cells (Figure 2C). Transfection miRNA cassette
3 resulted in a 55% to 83% reduction in plakoglobin
expression in MCF7 cells (Figure 2B). MCF7 clone 2A-1
from cassette 2 and clone 3C-3 from cassette 3 showed
a >80% reduction in plakoglobin, and T47D clone 2A-1
showed a 90% reduction in plakoglobin compared with
scramble sequence; therefore, these clones were selected
for use in the subsequent experiments. In all cases, the
reduction in plakoglobin expression was translated into
reduced g-catenin levels (Figure 1D), with high levels of
g-catenin detected on the cell membrane of control
MCF7 and T47D cells and reduced staining detected on
the cell membranes of plakoglobin-knockdown cell lines
(T47D cells shown in Figure 1E).
Real-time PCR analysis showed that knockdown of pla-
koglobin had no effect on total e-cadherin (Figure 2A, B,
C). However, protein levels were decreased by 6% in
MCF7 2A-1 and 6.5% in 3C-3 cells, whereas e-cadherin
was increased by 13% in T47D 2A-4 cells, when normal-
ized to RNA polymerase, compared with control (Figure
2D). Importantly, knockdown of plakoglobin resulted in
the translocation of the cell-cell adhesion proteins e-cad-
herin and b-catenin from the cell membrane into the
nucleus and cytoplasm (Figure 2E).
Reduced expression of plakoglobin increases proliferation
Reduced expression of plakoglobin resulted in a signifi-
cant increase in proliferation of both MCF7 and T47D
cells. In MCF7 cells a >80% reduction in plakoglobin led
to a 2.5-fold increase in proliferation at 72 hours and a
threefold increase at 96 hours compared with scramble
sequence, with no significant difference between miRNA
clones detected (P < 0.005 at 72 hours and P < 0.001 at
96 hours for 2A-1 and 3C-3) (Figure 3A). In T47D cells
in which plakoglobin expression was reduced by 90%,
proliferation was further increased with a twofold
increase in numbers of cells at 48 hours (P < 0.005), a
threefold increase at 72 hours (P < 0.005) and a fourfold
increase at 96 hours (P < 0.0001) compared with control
(Figure 3B). Furthermore, T47D 2A-4 cells showed sig-
nificantly increased proliferation compared with control
than did MCF7 2A-1 or 3C-3 clones (P < 0.005).
To ensure that miRNA knockdown was stable over
time, the levels of plakoglobin in tumor cells were ana-
lyzed at 24, 48, 72, and 96 hours for each cell-prolifera-
tion study. Figure 1C and 1D show that plakoglobin is
constitutively reduced in MCF7 and T47D miRNA
knockdown cells compared with control, and these cells

























Figure 1 Comparative expression of adhesion molecules .
Relative expression of (A) plakoglobin and (B) e-cadherin compared
with GAPDH ± SEM for T47D, HeLa, MDA-MB-231, MDA-MB-436, and
MCF7 cells, as assessed with real-time PCR. (C) Western blots
showing protein expression of g-catenin, e-cadherin, and RNA
polymerase from MCF7, T47D, HeLa, and MDA-MB-231 cells.
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Figure 2 Relative expression of plakoglobin and e-cadherin compared with GAPDH ± SEM before and after siRNA knockdown. (A)
Scramble sequence or miRNA cassette 2 in MCF7 cells; (B) scramble sequence or miRNA cassette 3 in MCF7 cells; and (C) scramble sequence or
miRNA cassette 2 in T47D cells. (D) Western blots showing g-catenin and e-cadherin expression after transfection with scramble sequence or
miRNA cassettes 2 and 3. (E) Immunohistochemical staining for g-catenin, e-cadherin, and b-catenin (green). In the control cells, g-catenin, e-
cadherin, and b-catenin are expressed on the cell surface clearly demarcating the cell-cell junctions. In the knockdown lines, g-catenin staining is
reduced, and e-cadherin and b-catenin are detected in the nucleus and the cytoplasm.
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Figure 3 Growth curves of control and knockdown cells. Mean ± SEM for (A) MCF7 and (B) T47D control and plakoglobin knockdown cells.
(C, D) Relative expression of plakoglobin over the 96-hour time course of the cell-proliferation experiment in control and knockdown MCF7 and
T47D cells, respectively. (E, F) The effects of plakoglobin expression on tumor cell adhesion. (E) Spheroid formation and (F) the percentage of
cells adhering to a confluent monolayer of cells of an identical cell type after 2 hours of co-culture. Data shown are expressed as mean ± SEM
(*P < 0.005, by one-way ANOVA followed by the Dunnett two-sided multiple comparison test).
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Reduced plakoglobin reduces cell-cell adhesion
A key early step in the metastatic process is the break-
ing away and dissemination of cells from the primary
tumor mass. To investigate the effect of plakoglobin
expression on cell-cell adhesion, we analyzed the ability
of control and knockdown cell lines to form three-
dimensional spheroid structures in agar. Figure 3E
shows control MCF7 cells growing as spheroids on agar,
demonstrating that these cells were able to form exten-
sive bonds with surrounding cells. Control T47D, which
expressed sixfold more plakoglobin than did control
MCF7 cells (see Figure 1A), grew as a much tighter
spheroid. Reducing plakoglobin levels resulted in a com-
plete loss of spheroid formation in MCF7 cells; both
2A-1 and 3C-3 cells grew as monolayers across the sur-
face of the agar, indicating that these cell lines no longer
form strong intercellular bonds. Similarly, reducing pla-
koglobin in T47D cells resulted in decreased cell-cell
adhesion, with 2A-4 cells growing in a less-compact
spheroid formation than control cells and cells at the
edge of the spheroid growing in a monolayer. The
reduced cell-cell adhesion after loss of plakoglobin was
confirmed by measuring the ability of DiD-labeled con-
trol and knockdown cells to adhere to a confluent cell
monolayer of the corresponding cell type. Measurement
of the percentage of cells binding to a monolayer after 2
hours (Figure 3F) showed that 19.23% ± 2.6% of DiD-
labeled MCF7 control cells bound to unlabeled control
cells, compared with 2.71% ± 0.30% MCF7 2A-1 cells
binding to unlabeled 2A-1 cells and 2.54% ± 0.26% 3C-3
cells binding to unlabeled cells. In addition, T47D con-
trol cells were significantly more adhesive than T47D
2A-4 cells; 19.01% ± 2.79% of control cells adhered to a
monolayer of the same cell type compared with 4.21% ±
1.06% of 2A-4 cells (P < 0.005), demonstrating that
reduced expression of plakoglobin significantly reduces
cell-cell adhesion.
Effects of plakoglobin expression on tumor cell invasion
and migration
As invasion of cancer cells into the surrounding tissue
and vasculature is an essential step for initiation of
metastasis, we next investigated whether altering plako-
globin levels affects invasion through a basement mem-
brane. Reducing expression of plakoglobin significantly
increased MCF7 and T47D tumor-cell invasion through
8-µm pores in a Matrigel-coated membrane at 24 hours:
89.8% of MCF7 2A-1 cells and 86.5% of MCF7 3C-3
cells that migrated trough an uncoated membrane also
invaded through Matrigel compared with 36.6% of
MCF7 control cells (P < 0.001 for both knockdown cell
lines compared with control). Similar proinvasive effects
were also observed in plakoglobin-knockdown T47D
cells: 63.6% of T47D 2A-4 cells invaded through
Matrigel compared with just 1.3% of T47D control cells
(P < 0.001; 2A-4 versus control) (Figure 4B). In the
absence of a basement membrane, plakoglobin-knock-
down cells were significantly more migratory than were
control cells (250 ± 50.4 MCF7 2A-1 cells and 248 ±
54.2 MCF7 3C-3 cells migrated through 8-µm pores
compared with 1.3 ± 2.1 MCF7 control cells) over a 24-
hour period. These data imply that reduced expression
of plakoglobin promotes cell migration toward a chemo-
tactic agent.
As knockdown cells had increased ability to invade
through an artificial basement membrane compared with
control, we used a wound-healing assay to investigate
whether plakoglobin expression altered cell motility in the
absence of a chemotactic agent. No significant differences
in cell motility were observed between MCF7 control and
plakoglobin-knockdown cells over a period of 72 hours
(Figure 4D), with cell tracking showing individual cells
moving at an average of (23 ± 9 μm/h) for control; (27 ± 8
μm/h) for 2A-1 and (29 ± 9 μm/h) for 3C-3. In contrast,
significantly increased cellular movement was observed in
T47D 2A-4 cells compared with control; after 24 hours,
29.6% ± 3.2% of the wound was closed in 2A-4 cells com-
pared with 3.3% ± 2.4% for control (P < 0.0001), increasing
to 57.8% ± 4.2% in 2A-4 and 16.7% ± 3.5% in control cells
after 48 hours (P < 0.0001; Figure 4E). Average cell move-
ment measured by individual cell tracking was (11.5 ± 4.8
μm/h) for control and (18.6 ± 8.4 μm/h) for 2A-4 cells,
clearly demonstrating that loss of plakoglobin expression
is associated with a significant increase in cell motility,
potentially leading to increased tumor cell spread.
Effects of plakoglobin on expression of the tumor-
suppressor molecule NM23-H1
Reduced expression of NM23-H1 has been shown to
disrupt cell-cell adhesion mediated by e-cadherin, result-
ing in b-catenin nuclear translocation [25]. Furthermore,
silencing of this gene promotes cellular scattering, moti-
lity, and extracellular matrix invasion [26]. We therefore
investigated the effects of plakoglobin knockdown on
expression of NM23-H1. As shown in Figure 4E redu-
cing expression of plakoglobin by >80% resulted in a sig-
nificant decrease of NM23-H1 in MCF7 2A-1 cells (P <
0.005) and T47D 2A-4 (P < 0.005) cells. In contrast,
expression of NM23-H1 was not significantly decreased
in MCF7 3C-3 cells (P = 0.08 compared with control),
implying that prometastatic effects seen after plakoglo-
bin knockdown may not be due to reduced expression
of MN23-H1.
Effects of plakoglobin on tumor cell growth and
dissemination in vivo
As the in vitro data showed that reduced plakoglobin
expression increased the prometastatic phenotype of
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Figure 4 Effects of plakoglobin expression on tumor cell invasion, migration, and expression of the tumor-suppressor gene NM23-H1.
(A, B) Histograms of mean ± SEM percentage of MCF7 (A) and T47D (B) tumor cell invasion through a basement membrane matrix (Matrigel)-
coated membrane compared with an uncoated membrane. Histograms showing mean ± SEM percentage of wound closure by MCF7 cells 24,
48, and 72 hours after scratch (C), and T47D cells 24 and 48 hours after scratch (D). (E) Expression of the tumor-suppressor gene, NM23-H1, in
control and plakoglobin-knockdown MCF7 and T47D cells. (*P < 0.005, by one-way ANOVA followed by the Dunnett two-sided multiple-
comparison test).
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MCF7 and T47D cells, we next investigated the effects
of reduced plakoglobin on tumor cell growth and disse-
mination into the circulation in vivo. miRNA knock-
down of plakoglobin resulted in a significant increase in
MCF7 and T47D tumor growth in the mammary fat
pads of nude mice (Figure 5A and 5C). At 32 days after
inoculation of tumor cells, MCF7 3C-3 tumors mea-
sured 281.43 ± 54.31 mm3, and control tumors mea-
sured 184.21 ± 34.93 mm3 (P < 0.001), with plakoglobin
expression accounting for 30.7% of the total variance.
Furthermore, mammary fat pad inoculation of T47D
cells resulted in a 55-fold increase in growth of T47D
2A-4 cells compared with control cells (Figure 5C).
Real-time PCR analysis of tumors after extraction
confirmed that plakoglobin expression remained sup-
pressed in knockdown cells in vivo (Figure 5B and 5C).
MCF7 cells have previously been shown to home to
and grow in mouse long bones when inoculated directly
into the bloodstream [27]. We therefore analyzed the
long bones of tumor-bearing mice for evidence of meta-
static tumor growth. Microcomputed tomography analy-
sis of tibiae and femurs from mice bearing MCF7 cells
confirmed that no evidence existed of osteolytic lesions
or tumor-induced bone loss in any mice bearing mam-
mary fat pad tumors. In the absence of late-stage metas-
tases (tumor in bone), we measured the effects of
altered plakoglobin expression on an early metastatic





Figure 5 Effects of plakoglobin expression on tumor growth in vivo. Ten Balb/c nude mice per group were inoculated with 1 × 105 MCF7
control or MCF7 3C-3 cells (A) or 1 × 105 T47D control or T47D 2A-4 (B) into the fifth and tenth mammary fat pads. Tumors were measured
twice per week, and all animals were killed 32 (MCF7) or 34 (T47D) days after tumor implantation. Data show mean ± SEM tumor volume over
time. (C) Plakoglobin expression in excised MCF7 control and 3C-3 tumors. (D) Plakoglobin expression in excised T47D control and 2A-4 tumors.
PCR data are shown as a percentage of GAPDH. (*P < 0.05, by one-way ANOVA, followed by the Dunnett two-sided multiple comparison test).
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bloodstream in mice bearing MCF7 control tumors with
those in mice bearing MCF7 3C-3 tumors of equal
volume (Figure 6A). Blood from tumor-free animals was
used as a negative control. Mice bearing 1 cc MCF7 3C-
3 tumors had >2.5 times more tumor cells per millilitre
of blood than did mice with 1-cc MCF7 control tumors,
implying that reduced plakoglobin increases tumor cell
shedding from the primary site into the circulation. No
colonies formed by day 7 after plating of the 165
EpCAM-positive cells isolated from MCF7 control sam-
ples or tumor-free controls (Figure 6B). In contrast, 19
colonies grew from a total of 522 cells isolated from
MCF7 3C-3 blood samples, showing that the EpCAM-
positive population isolated from animals with plakoglo-
bin knockdown tumors contains increased numbers of
viable tumor cells.
Discussion
In this study, we established that loss of plakoglobin
leads to significant changes in breast cancer cell pheno-
types, indicative of increased capacity for invasive
growth. Accumulating evidence suggests that adhesive
interactions are critical in the process of metastatic
tumor dissemination and that adhesion molecules can
act as both positive and negative modulators of the
metastatic process [reviewed in [28]]. The g-catenin-e-
cadherin complex promotes homotypic tumor cell adhe-
sion, maintaining intercellular contacts that confine cells
to the primary tumor site. Many studies have shown a
correlation between reduced e-cadherin expression and
increased metastasis both in laboratory models and in
clinical samples; however, a direct functional role of
g-catenin in this process has not been shown [29-33].
Evidence from clinical studies suggests that reduced
expression of plakoglobin in human breast cancers is
associated with increased tumor progression and adverse
clinical outcome [34-36]. Additionally, translocation of
g-catenin from the membrane to the cytoplasm has
been shown in breast cancers with a more-aggressive
phenotype [37]. Fitting with our hypothesis that reduced
plakoglobin expression increases the metastatic pheno-
type of cancer cells, we observed very low levels of pla-
koglobin in the highly metastatic cancer cell lines:
MDA-MB-231, MDA-MB-436, and HeLa, higher levels
of plakoglobin in weakly metastatic MCF7 cells, and
very high levels in nonmetastatic T47D cells. In accor-
dance with previously published studies of human breast
cancer biopsies, we found that cells with low levels of
plakoglobin expressed low levels of e-cadherin, and sig-
nificantly more e-cadherin was detectable in nonmeta-
static cell lines. Interestingly, levels of plakoglobin and
e-cadherin not only correlated with each other, but also
appeared to correlate with the metastatic potential of
the cell lines tested, implying that loss of this catenin-
cadherin complex is directly involved in the metastatic
process.
In the current study, we investigated the specific
effects of reduced plakoglobin expression on tumor cell
metastasis. Breast cancer metastasis is initiated by the
transition of epithelial cancer cells to a mesenchymal







Figure 6 Effects of plakoglobin expression on tumor cell
shedding into the bloodstream. (A) Numbers of circulating tumor
cells per milliliter of blood isolated from five mice bearing control
MCF7 cells and five mice with MCF7 3C3 tumors. Tumor cells were
isolated from mice with equal tumor volume (1 cm3 per mouse),
and non-tumor-bearing mice were used as a control. Cells from
each group were sorted into one well of a 96-well plate, and (B)
the numbers of cells isolated from the circulation with clonogenic
potential are shown. (*P < 0.005, compared with MCF7 control cells,
by one-way ANOVA followed by the Dunnett two-sided multiple-
comparison test).
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plakoglobin causes translocation of intercellular adhesion
proteins e-cadherin and b-catenin from the cell mem-
brane to the nucleus and the cytoplasm; these processes
are strongly associated with epithelial-to-mesenchymal
transition [26,38,39]. These prometastatic changes have
been linked with downregulation of the tumor suppres-
sor NM23-H1 [25]. In the current study, NM23-H1
expression was reduced in T47D 2A-3 and MCF7 2A-1
cells; however, NM23-H1 was unaltered in MCF7 3C-3
cells, which were significantly more migratory and inva-
sive than MCF-7 2A-1 cells. Therefore, it appears that
although altering intercellular adhesion molecules can
downregulate NM23-H1, other interacting factors may
be necessary for silencing of this gene. Key events in
initiation of metastasis include tumor cell proliferation,
detachment of cells from the primary tumor, migration
toward the vasculature, and invasion into the blood and
lymphatic systems. Knocking down plakoglobin expres-
sion substantially increased the prometastatic potential
of both cell lines, increasing proliferation, reducing
intercellular adhesion, and increasing invasion. Tumor
cell migration was also increased in T47D knockdown
cells compared with control. Interestingly, alterations in
metastatic phenotype were more pronounced in T47D
than in MCF7 cells. These observations may be due to
the differences in plakoglobin expression between the
two cell lines: T47D miRNA knockdown cells express
between 19- and 21-fold lower plakoglobin levels com-
pared with control, whereas plakoglobin expression in
MCF7-knockdown cells is six- to eightfold lower com-
pared with MCF7 control. MCF7 2A-1 cells that show a
sixfold reduction in plakoglobin compared with control
are less invasive and migratory than MCF7 3C-3 cells,
whose plakoglobin expression is reduced eightfold com-
pared with control. These data strongly indicate that the
level of plakoglobin expression within a breast cancer
cell specifically correlates with its ability to undergo
events involved in escape of tumor cells from the pri-
mary site.
For a metastatic tumor to grow at a distal site, tumor
cells must be able to invade the circulatory system, sur-
vive in the bloodstream, and home to and colonize a
specific metastatic site [23,28,40]. In accordance with
our in vitro findings, plakoglobin-knockdown cells grew
significantly faster than control cells when inoculated
into the mammary fat pads of balb/c nude mice. In
addition, increased numbers of EpCAM-positive tumor
cells were isolated from whole blood in mice with
MCF7 3C-3 tumors compared with controls, and the
cells were viable and able to form colonies when grown
in culture. These data indicate a higher degree of tumor
cell dissemination into the circulation from mammary
tumors with low levels of plakoglobin than from tumors
expressing high levels of this gene. Despite high levels of
circulating EpCAM-positive cells in mice with MCF7
3C-3 tumors, metastatic tumor growth was not detected
in the bones of any animals. This finding may be due to
MCF7 cells being unable to undergo the late stages of
metastases (bone homing and colonization), although
MCF7 cells have previously been used to induce breast
cancer growth in bone after intracardiac inoculation
[41]. The most likely explanation for this finding is that
mice used in the current study were 10 to 12 weeks old
when tumors were inoculated, and we and others have
shown tumors do not take if animals that are older than
8 weeks. It is hypothesized that high bone turnover, as
seen in young animals, is critical for human tumor
metastasis to mouse bone [41,42]. We were unable to
test this hypothesis in the mammary fat pads of 6-week-
old animals, as the fat pads were too small to inoculate.
It is also possible that any tumor metastases present in
bone were undetectable because of the short period of
these experiments (~5 weeks compared with 12 weeks
required for metastatic lesions to develop in mouse
bones after intracardiac inoculation of MCF7 cells) [42].
The effects of plakoglobin expression on tumor cell
homing and colonization of distal organs clearly warrant
further investigation and will form part of our future
research strategy.
Conclusion
In conclusion, this study is the first to show that
reduced plakoglobin expression results in translocation
of intercellular adhesion proteins e-cadherin and b-cate-
nin from the cell membrane to the nucleus and cyto-
plasm, as well as increasing cell-cell detachment,
invasion, and intravascular dissemination of breast can-
cer cells. Taken together, our results show that plakoglo-
bin has a functional role in the metastatic process; it
may therefore be a suitable prognostic marker for breast
cancer metastasis and be considered a potential thera-
peutic target.
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